Australia markets open in 2 hours 18 minutes

Neurocrine Biosciences, Inc. (NBIX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
110.54+2.25 (+2.08%)
As of 03:42PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close108.29
Open108.48
Bid110.40 x 900
Ask110.43 x 800
Day's range108.48 - 110.58
52-week range75.25 - 129.29
Volume487,675
Avg. volume803,303
Market cap10.627B
Beta (5Y monthly)0.52
PE ratio (TTM)184.23
EPS (TTM)0.60
Earnings date06 Feb 2023
Forward dividend & yieldN/A (N/A)
Ex-dividend date29 Dec 1995
1y target est127.75
  • Zacks

    Catalent (CTLT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

    Catalent (CTLT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Zacks

    Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy?

    Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Motley Fool

    Why Voyager Therapeutics Stock Is Sinking This Week

    Shares of the gene therapy company Voyager Therapeutics (NASDAQ: VYGR) were down by a little over 18% from their intraweek high as of 11:44 a.m. ET Friday, according to data provided by S&P Global Market Intelligence. Rather, Voyager's shares seem to be reverting to the mean following their enormous run-up earlier this month. As a refresher, the biotech's shares spiked by as much as 76% during the first two weeks of January as a result of the company's lucrative gene therapy deal with Neurocrine Biosciences (NASDAQ: NBIX).